SSA
RPRX icon

Schonfeld Strategic Advisors’s Royalty Pharma RPRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Buy
+26,261
New +$1.37M 0.01% 1247
2026
Q1 		– Sell
-118,748
Closed -$4.59M – 2606
2025
Q4 		$4.59M Buy
+118,748
New +$4.53M 0.02% 573
2025
Q3 		– Sell
-15,445
Closed -$556K – 2522
2025
Q2 		$556K Sell
15,445
-31,107
-67% -$1.03M ﹤0.01% 1513
2025
Q1 		$1.45M Sell
46,552
-32,590
-41% -$1.03M 0.01% 1125
2024
Q4 		$2.02M Buy
79,142
+34,537
+77% +$916K 0.01% 824
2024
Q3 		$1.26M Buy
44,605
+30,528
+217% +$846K 0.01% 1079
2024
Q2 		$371K Buy
14,077
+3,065
+28% +$85K ﹤0.01% 1598
2024
Q1 		$334K Sell
11,012
-5,582
-34% -$165K ﹤0.01% 1605
2023
Q4 		$466K Buy
16,594
+5,757
+53% +$158K ﹤0.01% 1308
2023
Q3 		$294K Sell
10,837
-238,640
-96% -$7.09M ﹤0.01% 1328
2023
Q2 		$7.67M Buy
249,477
+198,462
+389% +$6.72M 0.07% 405
2023
Q1 		$1.84M Sell
51,015
-162,222
-76% -$6.01M 0.02% 713
2022
Q4 		$8.43M Buy
213,237
+191,437
+878% +$7.99M 0.07% 345
2022
Q3 		$876K Sell
21,800
-4,167
-16% -$178K 0.01% 1355
2022
Q2 		$1.09M Sell
25,967
-50,287
-66% -$2.06M 0.01% 985
2022
Q1 		$2.97M Buy
76,254
+14,964
+24% +$588K 0.03% 603
2021
Q4 		$2.44M Buy
+61,290
New +$2.38M 0.02% 656
2021
Q3 		– Sell
-8,843
Closed -$362K – 2421
2021
Q2 		$362K Sell
8,843
-97,237
-92% -$4.14M ﹤0.01% 1356
2021
Q1 		$4.63M Buy
106,080
+81,080
+324% +$3.84M 0.06% 444
2020
Q4 		$1.25M Sell
25,000
-7,418
-23% -$315K 0.02% 733
2020
Q3 		$1.36M Buy
+32,418
New +$1.39M 0.03% 617

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schonfeld Strategic Advisors's RPRX Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Royalty Pharma (RPRX) in Q2 2026: 26,261 shares worth $1.47M. The stake represents 0.01% of the portfolio and ranks #1247 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in RPRX as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in RPRX in Q3 2020 and has held it in 21 quarters since. The position peaked at $8.43M in Q4 2022. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Schonfeld Strategic Advisors held 26,261 shares of Royalty Pharma worth $1.47M as of Q2 2026.
  • Royalty Pharma was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Royalty Pharma made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1247 holding.
  • Schonfeld Strategic Advisors first reported a position in Royalty Pharma in Q3 2020 and has held it in 21 quarters since.
  • Schonfeld Strategic Advisors's Royalty Pharma position peaked at $8.43M in Q4 2022.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.